1-乙酰氨基金刚烷，CAS 登记号 880-52-4，由济南圣和化工有限公司现货供应，可提供纯度 按批次COA提供(不公开发布) 的规格，下游主要用于有机化学品。支持样品与小批量试用，批量价格请联系我们获取，验收以批次 COA 为准。
有机化学品
每批随货提供 COA；可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号，一个工作日内回复报价。
本页已列出 1-乙酰氨基金刚烷 的 CAS 号：880-52-4，可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布)，包装形式为 按订单/批次确认(不公开发布)，特殊规格可在询价时说明。
主要涉及有机化学品。
来信 info@591daili.com 或 WhatsApp 联系，提供产品名称、CAS 号与数量，确认价格与交期后即可安排发货，验收以批次 COA 为准。
1-Acetamidoadamantane · CAS 880-52-4 · C12H19NO. UNII 5283Y1VOII.
| CAS Registry Number | 880-52-4 |
|---|---|
| PubChem CID | 64153 |
| Molecular formula | C12H19NO |
| IUPAC name | N-(1-adamantyl)acetamide |
| UNII (FDA) | 5283Y1VOII |
| Molecular Weight | 193.28 |
|---|---|
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 1 |
| Exact Mass | 193.146664230 |
| Monoisotopic Mass | 193.146664230 |
| Topological Polar Surface Area | 29.1 |
| Heavy Atom Count | 14 |
| Formal Charge | 0 |
| Reported hazard statements | H302 (91.1%), H312 (91.1%), H332 (91.1%) |
|---|
H302 (91.1%): Harmful if swallowed [Warning Acute toxicity, oral]
H312 (91.1%): Harmful in contact with skin [Warning Acute toxicity, dermal]
1-Acetamidoadamantane; 880-52-4; n-adamantylacetamide; N-1-Adamantylacetamide; Acetamide, N-tricyclo(3.3.1.13,7)dec-1-yl-; 5283Y1VOII; N-ACETYL AMANTADINE; Acetamide, N-tricyclo[3.3.1.13,7]dec-1-yl-; NSC-527917; DTXSID9061255; N-Tricyclo(3.3.1.13,7)dec-1-ylacetamide; N-(TRICYCLO(3.3.1.13,7)DEC-1-YL)ACETAMIDE; AMANTADINE HYDROCHLORIDE IMPURITY B (EP IMPURITY); AMANTADINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]; RefChem:1113325; 212-914-9
CAS 880-52-4; molecular formula C12H19NO; molecular weight — g/mol.
1-Acetamidoadamantane, 880-52-4, n-adamantylacetamide, N-1-Adamantylacetamide, Acetamide, N-tricyclo(3.3.1.13,7)dec-1-yl-, 5283Y1VOII.
Hazard statements reported: H302, H312, H332.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.